ID
45884
Descripción
Principal Investigator: Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000980 Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced.
Link
Palabras clave
Versiones (1)
- 18/11/23 18/11/23 - Simon Heim
Titular de derechos de autor
Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Subido en
18 de noviembre de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000980 PD-1 Blockade in Non-Small Cell Lung Cancer
This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- This subject sample mapping data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
Similar models
This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- This subject sample mapping data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
C1299222 (UMLS CUI [1,2])
C1518422 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
C0027627 (UMLS CUI [2,1])
C0007601 (UMLS CUI [3,1])
C0450429 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,2])
C0027651 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
C5575037 (UMLS CUI [1,2])
C1285573 (UMLS CUI [1,3])
C5575037 (UMLS CUI [1,2])
C1294197 (UMLS CUI [1,3])
Sin comentarios